ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -917.80K | -950.00K | -1.01M | -5.11M | -5.03M |
| Total Depreciation and Amortization | 7.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 470.20K | 512.50K | 590.00K | 4.71M | 4.70M |
| Change in Net Operating Assets | 45.70K | -45.50K | -28.50K | -47.50K | -58.90K |
| Cash from Operations | -394.20K | -482.90K | -448.90K | -452.20K | -387.40K |
| Capital Expenditure | -6.40K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | 558.20K | 558.20K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.90K | -- | -- | -- | -- |
| Cash from Investing | -14.30K | -- | 0.00 | 558.20K | 558.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -45.40K | -40.00K | -40.00K | -40.00K | -- |
| Issuance of Common Stock | 1.56M | 1.56M | 1.67M | 1.22M | 115.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.50K | -7.50K | -- | -- | -- |
| Cash from Financing | 1.11M | 1.12M | 1.21M | 879.40K | 86.70K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 704.90K | 634.50K | 760.70K | 985.50K | 257.60K |
